Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.40 |
| ▸ | AURKA | O14965 | 3/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016517 | 0.85 | EGFR (0.42) | EGFRHDAC3ERBB2KDRHDAC4 | |
| SCHEMBL6016566 | 0.79 | LMNA (0.42) | EGFRRPS6KB1AURKA | |
| SCHEMBL15354441 | 0.76 | MAP4K4 (0.46) | EGFR | |
| SCHEMBL12943561 | 0.74 | MAP4K4 (0.36) | EGFR | |
| SCHEMBL15354445 | 0.74 | MAP4K4 (0.36) | EGFR | |
| SCHEMBL15354461 | 0.74 | MAP4K4 (0.36) | EGFR | |
| SCHEMBL6016571 | 0.73 | SMN1; SMN2 (0.67) | — | |
| SCHEMBL240657 | 0.71 | TP53 (0.41) | EGFRRPS6KB1 | |
| SCHEMBL179408 | 0.71 | JAK2 (0.35) | EGFR | |
| SCHEMBL21389725 | 0.71 | MAP4K4 (0.34) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244668-B1 | PURINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE THEREOF | UNIVERSITAIRE INSTELLING ANTWE (BE) | 2006-04-05 | — | — | EP | claimed |
| US-20030187261-A1 | Purine derivatives, process for their preparation and use thereof | USTAV EXPERIMANTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2003-10-02 | — | — | US | claimed |
| US-20030187261-A1 | Purine derivatives, process for their preparation and use thereof | USTAV EXPERIMANTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187261-A1 | Purine derivatives, process for their preparation and use thereof | DCK, DTYMK, CCNK | EGFR 3830/4885RPS6KB1 625/4885AURKA 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.